

NATURAL BIOCON (INDIA) LIMITED

Regd. Office: Cabin No. 1, C/309, Ganesh Meridian, Opp. Gujarat High Court, S. G. Highway,
Ahmedabad-380060, CIN: L24299GJ1992PLC018210, Email Id: info@naturalbiocon.in,
Website: www.naturalbiocon.in, Phone No.: 9409054403

06th February, 2021

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Ref.: Script Code: 543207

Dear Sir,

Sub.: Outcome of Board Meeting

With reference to above subject and in compliance with the SEBI (LODR) 2015, we hereby submit the outcome of the Meeting of the Board of Directors held on today i.e. 06th February, 2021 at 12:00 noon and concluded on 3:30 p.m.:-

- 1) Considered, adopted and approved Unaudited Financial Results for the quarter ended on 31st December, 2020.

You are requested to kindly take the same on record.

Thanking You

Yours faithfully,

For, Natural Biocon (India) Ltd

Rohitkumar Parikh
Managing Director
DIN: 00174964



Financial results by company

PART I		(Rs. in Lakhs)				
Statement of Standalone Unaudited Results for the Quarter and Nine months Ended 31/12/2020						
Particulars	Quarter Ended			Nine Months Ended		Previous year ended
	3 months ended (31/12/2020)	Preceding 3 months ended (30/09/2020)	Corresponding 3 months ended in the previous year (31/12/2019)	Year to date figures for current period ended (31/12/2020)	Year to date figures for the previous year ended (31/12/2019)	Previous year ended (31/03/2020)
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from Operation	11.46	3.68	0.00	15.14	0.00	0.00
Other income	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue (I + II)	11.46	3.68	0.00	15.14	0.00	0.00
2 Expenses						
(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	2.73	0.43	0.00	3.16	0.00	0.00
© Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(d) Employee benefits expense	0.45	0.15	0.54	0.75	1.69	1.58
(e) Finance Cost	0.01	0.00	0.00	0.01	0.00	0.01
(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
(g) Other expenses	0.24	0.02	0.01	0.31	7.72	1.58
Total expenses	3.43	0.60	0.55	4.23	9.42	3.17
3 Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)	8.02	3.09	(0.55)	10.90	(9.42)	(3.17)
4 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit / (Loss) before extraordinary items and tax (V - VI)	8.02	3.09	(0.55)	10.90	(9.42)	(3.17)
6 Tax expense - Provision for taxation						
Current Tax - Provision for taxation	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax						
7 Net Profit / (Loss) for the period	8.02	3.09	(0.55)	10.90	(9.42)	(3.17)
8 Other Comprehensive Income/(Loss) (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00
9 Total Comprehensive Income/(Loss) for the period	8.02	3.09	(0.55)	10.90	(9.42)	(3.17)
10 Paid up Equity Share Capital (Face value of Rs. 10/- each)	1137.28	1137.28	1137.28	1137.28	1137.28	1137.28
11 Earnings per equity share:						
(1) Basic	0.00	0.00	(0.00)	0.00	(0.00)	(0.00)
(2) Diluted	0.00	0.00	(0.00)	0.00	(0.00)	(0.00)

Notes:

- The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 06th February, 2021
- The Company has only single Reportable Business Segment.
- During the quarter ended 31st December 2020, 0 complaints was received and attended.
- Previous quarter's figures have been re-grouped / re-arranged wherever necessary.

Date: 06/02/2021
 Place: Ahmedabad

By Order of the Board of Directors
 For Natural Biocon (India) Limited

Rohitkumar J Parikh
 Managing Director
 DIN: 07394964





Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors of
Natural Biocon (India) Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Natural Biocon (India) Limited (the 'Company') for the quarter ended December 31, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIRJCFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SIZE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SANKET SHAH
CHARTERED ACCOUNTANT
MEM. NO. 150873
UDIN No. 21150873AAAABC2756



Date: 06-02-2021
Place: Ahmedabad